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Cardiac hypertrophy occurs in association with heart diseases and ultimately results in cardiac dysfunction and heart failure.
Histone deacetylases (HDACs) are post-translational modifying enzymes that can deacetylate histones and non-histone proteins.
Research with HDAC inhibitors has provided evidence that the class I HDACs are pro-hypertrophic. Among the class I HDACs,
HDAC2 is activated by hypertrophic stresses in association with the induction of heat shock protein 70. Activated HDAC2 triggers
hypertrophy by inhibiting the signal cascades of either Kr¨ uppel like factor 4 (KLF4) or inositol polyphosphate-5-phosphatase f
(Inpp5f). Thus, modulators of HDAC2 enzymes, such as selective HDAC inhibitors, are considered to be an important target for
heart diseases, especially for preventing cardiac hypertrophy. In contrast, class IIa HDACs have been shown to repress cardiac
hypertrophy by inhibiting cardiac-speciﬁc transcription factors such as myocyte enhancer factor 2 (MEF2), GATA4, and NFAT in
the heart. Studies of class IIa HDACs have shown that the underlying mechanism is regulated by nucleo-cytoplasm shuttling in
response to a variety of stress signals. In this review, we focus on the class I and IIa HDACs that play critical roles in mediating
cardiac hypertrophy and discuss the non-histone targets of HDACs in heart disease.
1.Introduction
Cardiac hypertrophy is an adaptive response to an initial
exogenous hypertrophic stimulus that leads to a maladaptive
state when the stress is prolonged [1]. Cardiac hypertrophy
is characterized by increased cell size, enhanced protein
synthesis, and heightened organization of the sarcomere. In
this state, fetal genes, such as natriuretic peptide precursor
type A (Nppa), myosin heavy polypeptide 7 (Myh7), and
skeletal alpha-actin, are reactivated whereas cardiac contrac-
tile proteins like myosin heavy polypeptide 6 (Myh6)a n d
calcium-handling proteins are repressed [2]. In addition,
immediate-early genes encoding c-fos,c - jun, and heat shock
proteins are upregulated [3, 4]. In humans, stresses such as
chronic hypertension and myocardial infarction can trigger
the heart to undergo remodeling processes characterized
by myocyte hypertrophy, myocyte death, and ﬁbrosis, often
resulting in pathological heart diseases including reduced
cardiac function, cardiomyopathy, and heart failure [5–
8]. Although it is believed that hypertrophy can be an
adaptive response to exogenous stresses, advanced cardiac
hypertrophy itself is associated with an increased risk of
morbidity and mortality [9, 10].
Histones have long N-terminal tails and are subject to
diverse post-translational modiﬁcations such as acetylation,
methylation, phosphorylation, ubiquitination, and sumoy-
lation. A well-characterized post-translational modiﬁcation
is acetylation, which occurs at the ε amino groups of lysine
residues in the core histone. Acetylation of chromatin plays
a central role in the epigenetic regulation of gene expression
in eukaryotic cells. Acetylation is regulated by two opposing
families of proteins, histone acetyltransferase (HAT), and
histonedeacetylases(HDACs).Recentevidencehasindicated
that diﬀerent HDACs participate in a variety of heart dis-
eases, such as arrhythmia, heart failure, and acute coronary
s y n d r o m e s ,a sw e l la si nc a r d i a ch y p e r t r o p h y[ 11–19].2 Journal of Biomedicine and Biotechnology
In mammals, there are four major classes of HDACs.
Class I HDACs (HDAC1, 2, 3, and 8) are widely expressed
and consist mainly of a catalytic domain. Class II HDACs
are divided into two subclasses, IIa (HDAC4, 5, 7, and 9)
and IIb (HDAC6 and 10). Class III HDACs are NAD(+)-
dependent and are referred to as sirtuins (SIRT1-7). Most
class IIa HDACs show cell-type-restricted expression pat-
terns. Although many HDACs have a highly conserved
domain, recent studies show that class I and IIa HDACs
have opposing roles in regulating cardiac hypertrophy, and
evidence for the mechanisms by which the distinct classes of
HDACs act to control cardiac hypertrophy is growing. In this
paper, we focus on the pathophysiological roles of class I and
IIa HDACs in cardiac hypertrophy.
2.HeartDiseasesRegulatedbyClassIHDACs:
CardiacGrowth,Proliferation,
Differentiation, Fibrosis, Ischemic Heart
Disease,andArrhythmia
HDACs are implicated as a regulator in various pathological
heart diseases such as ﬁbrosis, arrhythmia, ischemic heart
diseases, and heart failure. Cardiac arrhythmia is related
to a variety of cardiac stressors such as ischemia and an
increase in wall stress. It is also associated with the renin-
angiotensin-aldosterone system. A recent study indicated
that the HDAC inhibitor, TSA, inhibits atrial ﬁbrosis and
arrhythmicinducibilityandpartiallynormalizesconnexin40
expression without changes in the angiotensin level in the
Hopx transgenic mouse cardiac hypertrophy model [12].
Our group and others have demonstrated that myocar-
dial ﬁbrosis is reduced by HDAC inhibitors such as TSA
and sodium valproate either in mice with left ventricular
hypertrophy induced by aortic banding or in rats with
right ventricular hypertrophy induced by pulmonary artery
banding [15, 20, 21]. In addition, chemical HDAC inhibition
was shown to reduce infarct size and improve ventricular
function recovery in a model of myocardial ischemia and
reperfusion injury, which suggests a novel therapeutic target
for acute coronary syndromes [16, 17]. Sustained cardiac
hypertrophic stimuli may lead to cardiomyopathy and
heart failure. Likewise, heart failure with high mortality
was prevented by apicidin derivatives with class I HDAC
speciﬁcity in mice with heart failure induced by thoracic
aortic constriction [13].
We [14] and other research groups [15, 20, 22]r e p o r t e d
that class I and II broad HDAC inhibitors could prevent car-
diac hypertrophy in animal models. We demonstrated that
class I HDACs are required for the hypertrophic response
in aortic banding or angiotensin II infusion-induced hyper-
trophy animal models with class I HDAC-selective HDAC
inhibitor. Chemical HDAC inhibitors such as TSA or
valproate induced the partial regression of pre-established
cardiac hypertrophy. We were the ﬁrst to show that class
I HDACs may play a pro-hypertrophic role in the heart.
Recently, another group reported similar results that broad-
spectrum HDAC inhibitors such as TSA or scriptaid blunt
the cardiac hypertrophy induced by aortic banding [15].
In rat neonatal cardiomyocytes, HDAC inhibition by TSA
was also reported to blunt a stress-induced hypertrophic
marker [22]. In addition, our group reported that sodium
valproate, an alternate HDAC inhibitor, prevents right ven-
tricular hypertrophy induced by pulmonary artery banding
in rats [21]. Considering that class II HDACs work as anti-
hypertrophic mediators, prevention of cardiac hypertrophy
with nonspeciﬁc HDAC inhibitors strongly suggests that
class I HDAC may function as a pro-hypertrophic regulator
in the heart. These suggestions would be further supported
by the reports that class I HDAC-selective inhibitors still
show anti-hypertrophic eﬀects [13, 14].
Recent studies have indicated that the class I HDACs
(HDAC1, 2, 3, and 8) are involved in the control of cardiac
growth, proliferation, and diﬀerentiation. Table 1 summa-
rizes the phenotype and function of HDAC1, HDAC2, and
HDAC3 in the heart. HDAC1 was reported to be a regula-
tor of cardiomyogenesis, cell proliferation, and embryonic
development. During cardiomyogenesis, downregulation of
HDAC1 promotes the expression of Nkx2.5, a critical regu-
lator of cardiac gene expression and heart development [23].
Disruption of the HDAC1 gene results in embryonic death
before E10.5 as the result of severe proliferation defects [24].
These data suggest that HDAC1 is an important mediator in
cardiac diﬀerentiation and early embryonic development.
Recent evidence implicates HDAC2 as a positive regula-
tor of the hypertrophic response during embryonic develop-
ment and in the adult heart. For example, HDAC2-deﬁcient
mice generated by a gene-trap technique show partial
postnatal lethality, increased numbers of mitochondria, and
abnormal sarcomere structure [26]. In addition, loss of
HDAC2 makes the heart resistant to hypertrophic stimuli
through the increased expression of inositol polyphosphate-
5-phosphatase f (Inpp5f). The increased expression of Inpp5f
is associated with activation of glycogen synthase kinase
3β (GSK3β). In contrast, transgenic mice overexpressing
HDAC2 in the heart are sensitive to hypertrophic stimuli
[26].
However, another group recently reported a diﬀerent
ﬁnding that HDAC2-null mice generated by use of the
Cre/loxP system die within 24 hours after birth [25]. The
most interesting diﬀerence between the studies of Trivedi et
al. [26] and Montgomery et al. is that HDAC2 deletion by
lacZ insertional mutation removes the region with exons 9–
14, in the C-terminus of HDAC2 whereas the conditional
deletion regions of HDAC2 include exons 2–4. Although
HDAC2 consists mainly of the HDAC catalytic domain,
the catalytic domain extends from partial exon 2 to exon
9. Therefore, the catalytic domain of HDAC2 seems to be
implicated in postnatal viability. The diﬀerent approaches to
HDAC2 mutation resulted in distinct ﬁndings in response to
hypertrophic stimuli such as chronic isoproterenol or aortic
banding. For example, heart-speciﬁc deletion of HDAC2 did
not result in an increased response to hypertrophic stimuli
whereas HDAC2 disruption by lacZ insertional mutation
prevented cardiac hypertrophy in response to hypertrophic
stimuli [25].
HDAC3 is suggested to function as a regulator of
cardiac myocyte proliferation during cardiac developmentJournal of Biomedicine and Biotechnology 3
Table 1: The physiological role of class I and class IIa HDACs in cardiac development and heart diseases.
HDAC subtype Model Phenotype Disease functions in the heart References
HDAC1 P19CL16 cells Diﬀerentiation HDAC1 protein was decreased during
cardiomyogenesis Liu et al. [23]
HDAC1-deﬁcient
mice
Proliferation Embryo lethality because of proliferation
defects
Lagger et al. [24],
Montgomery et al. [25]
HDAC2
HDAC2 knockout
mice
Proliferation Proliferation rates of cardiac myocytes in
HDAC2 knockout mice were elevated Trivedi et al. [26]
HDAC2 knockout
mice
Proliferation Increase in proliferation at P1
Lethality after P1 Montgomery et al. [25]
HDAC2 knockout
mice
Hypertrophy HDAC2 knockout mice are resistant to
cardiac hypertrophy Trivedi et al. [26]
HDAC2 transgenic
mice
Hypertrophy HDAC2 transgenic mice show cardiac
hypertrophy Trivedi et al. [26]
Aortic banding mice Hypertrophy HDAC2 and HSP70 cause cardiac
hypertrophy Kee et al. [14]
Hsp70 knockout mice
HDAC3
HDAC3 transgenic
mice
Proliferation HDAC3 transgenic mice show postnatal
cardiac myocyte proliferation Trivedi et al. [27]
HDAC3 knockout
mice
Hypertrophy HDAC3 knockout mice show massive
cardiac hypertrophy Montgomery et al. [28]
HDAC3 knockout
mice
Metabolism HDAC3 regulates cardiac energy
metabolism Montgomery et al. [28]
HDAC4 HDAC4 knockout
mice
HDAC4 knockout mice die perinatally
because of abnormal chondrocyte
hypertrophy
Vega et al. [29]
HDAC5 HDAC5 knockout
mice
Hypertrophy Mice lacking HDAC5 develop enlarged
hearts in response to pressure overload Chang et al. [30]
HDAC9 HDAC9 knockout
mice
Hypertrophy HDAC9 mutant mice develop cardiac
hypertrophy Zhang et al. [31]
[27]. For example, transgenic hearts with myocyte-speciﬁc
overexpression of HDAC3 show thickening in the ven-
tricular wall and interventricular septum and an increase
in phospho-histone H3 staining at neonatal day 1 (P1).
The mRNA expression of several cyclin-dependent kinase
inhibitors (p21, p27, p57, p16, and p15) is repressed in
HDAC3 transgenic mice at P1. However, at 2 months of
age, HDAC3 transgenic mice do not show an increase in
the proliferation index. The results of this study imply that
HDAC3 is related to cardiomyocyte proliferation rather than
to cardiac hypertrophy. Recently, another group demon-
strated a diﬀerent role and phenotype of HDAC3 in the
heart. In that study, although global deletion of HDAC3
resulted in embryonic death, heart-speciﬁc deletion of
HDAC3 resulted in severe cardiac hypertrophy and increased
expression of mitochondrial uncoupling genes at 3 months
of age, and the mice survived until 4 months of age [28].
HDAC3 knockout mice elicited a signiﬁcant increase in p21
expression [28].
Although HDACs have enzymatic activity to remove
acetyl groups from protein, their existence alone is also
important, because they can interact with numerous bind-
ing partners including transcription factors to form large
complexes. For example, the enzyme activity and binding
to MEF2 of class IIa HDACs play a critical role in a variety
of diseases. In particular, MITR, a splice variant of HDAC9
that lacks a deacetylase domain, is known to have anti-
hypertrophic action [31]. In this regard, studies should be
taken with caution to determine which mechanism of either
existence or activity is critical for the biological actions of
HDACs. Our groups have demonstrated that the enzymatic
activation of HDAC2 preceded the substantial hypertrophic
phenotype in response to hypertrophic stimuli whereas the
mutant form of HDAC2 did not result in a substantial
hypertrophic phenotype. These results suggest that HDAC2
activation rather than its presence is important to induce
cardiac hypertrophy [32].
Like the class IIa HDACs, the activities of the class I
HDACs are regulated by post-translational modiﬁcations.
The activity of HDAC1, HDAC2, and HDAC3 is mainly
regulated by the phosphorylation of the casein kinase
CK2 [33–35]. HDAC8 is phosphorylated by PKA [36].
For a better understanding of pathological heart diseases,
further experiments are necessary to determine whether
the phosphorylation status of the HDACs is modulated by
phosphatases.
In summary, although both are class I HDACs, HDAC2
and HDAC3 have diﬀerent functions in the regulation of
cardiac hypertrophy and proliferation. HDAC2 works to
cause cardiac hypertrophy accompanied by a repression
of proliferation whereas HDAC3 acts to inhibit cardiac
hypertrophy with increasing proliferation. We discuss the4 Journal of Biomedicine and Biotechnology
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Figure 1: The signaling cascade of class I and IIa HDACs in
the development of cardiac hypertrophy. Class I HDACs can
be regulated by the Hopx/HDAC2/HSP70/KLF4 pathway. Cardiac
hypertrophy is induced in Hopx transgenic mice through the
recruitment of HDAC2. Hypertrophic stresses including pressure
overload or agonist-induced HSP70 expression are followed by its
association with HDAC2. The resultant increase in HDAC2 activity
decreases the expression of anti-hypertrophic mediators including
KLF4 and Inpp5f. This diagram is adapted from the works of
Kook et al. [20] and Kee et al. [32, 38] (JCI, 2003; Circulation
Research, 2008; JMCC, 2009). Class II HDACs can be activated by
PKD or CaMK. They interact with MEF2. MEF2 also associates
with GATA4 and NFAT transcription factor. NFAT can be triggered
by calcineurin. Class IIa HDACs can repress cardiac hypertrophy
through MEF2 either directly or indirectly.
mechanism by which HDAC2 regulates cardiac hypertrophy
further in the next section.
3.HDAC2,aClass IHDAC,in
Cardiac Hypertrophy
Recently,byuseofHDAC2knockoutmiceortransgenicmice
and cardiomyocytes, our group and others have identiﬁed
that HDAC2, a class I HDAC, positively regulates cardiac
hypertrophy.Figure1showstheHopx/HDAC2/HSP70/KLF4
signal cascades that regulate prohypertrophy pathways in
the heart. Our hypothesis is supported by our previous
study with transgenic Hopx mice. Hopx, a cardiac-speciﬁc
regulator of gene transcription, is an unusual homeodomain
protein that is expressed in embryonic and postnatal cardiac
myocytes. Inactivation of Hopx causes severe developmental
cardiac defects with cardiac proliferation. Hopx transgenic
mice exhibit cardiac hypertrophy and cardiac ﬁbrosis result-
ing from recruitment of HDAC2 whereas Hopx mutants do
not develop hypertrophy or recruit HDAC2. The cardiac
hypertrophy induced in Hopx transgenic mice can be
prevented by HDAC inhibitors such as TSA and valproate
[20, 37]. Although previous studies showed an increase in
HDACactivityinHopxtransgenicmicecomparedwithwild-
type mice, little is known about changes in the activity
of each of the HDACs in cardiac hypertrophy. Thus, our
group focused on determining HDAC activity in response
to hypertrophic stimuli among the class I HDACs. We
observed that only HDAC2 activity was induced in response
to hypertrophic stimuli.
Heat shock proteins (HSPs) are induced by hypertrophic
stimuli [3]. Thus, we determined whether the induction of
HSPs in response to hypertrophic stresses induces cardiac
hypertrophy. We found that the novel HDAC2-interacting
partner HSP70 activates HDAC2 and induces cardiac hyper-
trophy. HDAC2 increased the cardiomyocyte cell size. In
addition, cardiac hypertrophy and HDAC2 activation were
blunted in HSP70 knockout mice [32]. These data strongly
suggested that the HSP70/HDAC2 axis is an important
mediator in the regulation of cardiac hypertrophy and
highlighted HSP70 as a regulator of HDAC2 activity in
response to hypertrophic stresses.
We next investigated whether HDAC2 could regulate
downstream targets in cardiomyocytes. In the cardiomy-
ocytes, Kr¨ uppel-like factor4 (KLF4) was shown to be a target
of HDAC2 and to repress Nppa, leading to the inhibition
of cardiac hypertrophy [38]. KLF4 overexpression blocked
the increase in Nppa transcript levels and [3H]-leucine
incorporation induced by 20% FBS. In contrast, KLF4
knockdownstimulatedhypertrophicphenotypes.Theresults
ofthisstudysuggestedthatKLF4isanovelanti-hypertrophic
regulator. Recently, Liao et al. reported that KLF4 functions
as a negative regulator of cardiac hypertrophy by use of the
cardiomyocyte-speciﬁc KLF4 knockout mice [39].
Like KLF4, Inpp5f is known to be a downstream target
of HDAC2 in mediating cardiac hypertrophy. HDAC2-
regulation of Inpp5f is mediated through the phosphatidyli-
nositol 3-kinase- (PI3K-) Akt-Gsk3β pathway, which is
important for growth control in heart. Overexpression of
HDAC2 suppresses Inpp5f expression, and accumulation
of phosphatidyl inositol-3,4,5-trisphosphate (PIP3) leads
to the recruitment of protein kinase Akt. Activated Akt
inactivates Gsk3β by its phosphorylation. Suppression of
Gsk3β activity relieves the inhibition of some hypertrophic
signaling pathways, such as c-Myc, GATA4, and β-catenin,
leading to cardiac hypertrophy [26]. In the case of HDAC2
deﬁciency, the decrease in Akt activity and increase in
Gsk3β activity result in resistance to cardiac hypertrophy.
Furthermore, hypertrophic responsiveness was shown to
be reduced in mice with Inpp5f overexpression whereas
knockout mice showed augmented hypertrophy [40].
4.Negative Regulation of Cardiac Hypertrophy
andHeart Failureby ClassIIaHDACs
The class IIa HDACs (HDAC4, HDAC5, HDAC7, and
HDAC9) are expressed in muscles and brain and have anJournal of Biomedicine and Biotechnology 5
N-terminal regulatory domain that mediates interactions
with transcription factors, coactivators, and corepressors
[41–43]. The underlying mechanism and functional role of
the class IIa HDACs in hypertrophy has been intensively
investigated by the Olson group by use of knockout mice.
Diverse hypertrophic stimuli lead to the activation of cardiac
HDAC kinases such as protein kinase C (PKC), protein
kinase D (PKD), and calcium/calmodulin-dependent pro-
tein kinase (CaMK). In this section, we describe how each of
the class II HDACs regulates and aﬀects cardiac hypertrophy
through signaling pathways and associated proteins.
HDAC4 is phosphorylated by activated CaMKII in
response to phenylephrine. Phosphorylated HDAC4 is
translocated into the cytoplasm by 14-3-3 protein, result-
ing in derepression of the MEF2 gene, which leads to
hypertrophic growth [44]. HDAC4 appears to interact
with and inhibit the activity of runt-related transcription
factor 2 (Runx2). HDAC4-null mice show skeletal defects
and chondrocyte hypertrophy, whereas overexpression of
HDAC4 inhibits chondrocyte hypertrophy and shows Runx2
loss of function of phenotypes [29].
HDAC5, an alternate class IIa HDAC, has similar
actions in regulating cardiac hypertrophy. Phosphorylation
of HDAC5 by PKC or PKD leads this protein to bind to 14-
3-3 protein, which stimulates the nuclear export of HDAC5.
In cardiomyocytes, an HDAC5 phosphorylation mutant was
shown to be resistant to the PKC signaling pathway and
to block cardiomyocyte hypertrophy [45]. Chang et al.
demonstrated that HDAC5 knockout mice develop cardiac
hypertrophy with age in response to pressure overload and
calcineurin signaling whereas overexpression of HDAC5
blocks hypertrophy [30]. Although little is known about
the role of HDAC7 in cardiac hypertrophy, this HDAC is
also regulated by shuttling [46]. By contrast, the role of
HDAC9 has been well scrutinized in cardiac hypertrophy
by use of knockout mice. Class IIa HDACs and MEF2-
interacting transcriptional repressor (MITR), a splice variant
of HDAC9, have MEF2 binding sites in the N-terminus and
anHDACcatalyticdomainintheC-terminalregion.HDAC9
mutant mice show cardiac hypertrophy with advanced age
in vivo and are hypersensitive to hypertrophic stimuli such
as thoracic aortic banding [31]. HDAC5/9 double knockout
mice show an even greater degree of cardiac hypertrophy
than mice lacking either HDAC5 or HDAC9 [30]. In addi-
tion, other pro-hypertrophic transcription factors including
GATA4andNFAThavebeenshowntoberepressedindirectly
by class IIa HDACs [47]. These transcription factors have
been shown to be associated with MEF2 [48]. Therefore,
class IIa HDACs also can repress the activity of these cardiac-
speciﬁc transcription factors though MEF2.Taken together,
these ﬁndings suggest that the class IIa HDACs function
as negative regulators of cardiac hypertrophy by repressing
MEF2/GATA4/NFAT-mediated gene expression [31, 49].
Although most of the class IIa HDACs can be shuttled
from the nucleus to the cytoplasm by phosphorylation in the
control of cardiac hypertrophy [50, 51], recent evidence has
shown that HDAC4 is subject to oxidative modiﬁcation in
the mediation of cardiac hypertrophy [52]. When HDAC4
oxidation is induced by hypertrophic stimuli, thioredoxin1,
a 12-kDa antioxidant, regulates the nucleocytoplasmic shut-
tling of HDAC4. In addition, cysteine residues in HDAC2
are subject to nitrosylation modiﬁcation in neurons [53,
54]. Therefore, like phosphorylation, other forms of post-
translational modiﬁcation may be critical mechanisms in the
regulation of cardiac hypertrophy.
5. ClassIIIHDACs:Aging and Stress
Class III HDACs consist of seven Sirt isoforms (Sirt 1 to
Sirt 7). The Sirts, known as sirtuins, are NAD(+)-dependent
acetyl-lysine deacetylases. The Sirts have been shown to be
involved in aging and protection against oxidative stress in
the heart [55, 56]. Heart-speciﬁc moderate overexpression
of Sirt 1 in mice results in the retardation of aging and a
protective response to oxidative stress [57]. As for Sirt 1,
similar results have been shown for Sirt 3 and Sirt7 in regu-
lating oxidative stress-mediated cell death in cardiomyocytes
[58, 59]. Considering the beneﬁcial eﬀects of Sirts, intensive
studies of Sirt activators will enhance our understanding of
the underlying mechanism in heart diseases. Sirt activators
are being developed, and clinical trials have been conduced
forsomemetabolicdiseasessuchasdiabetes[60].Wesuggest
that Sirt may be a critical target in mediating cardiovascular
diseases.
6.DeacetylationofNonhistone Proteinsby
HDACs:TranscriptionFactorsand
Cytoskeleton Proteins
Non-histone proteins have been identiﬁed as substrates for
HDACs [61]. Many studies have demonstrated that diﬀerent
HDACs target various transcription factors in cancer cells,
during protein repair, in immune reactions, and in redox
regulation. For example, p53, the most commonly mutated
gene in cancer cells, is deacetylated by HDAC1 and SIRT1
(Sir2 alpha) [62, 63]. SRY, a sex-determining region on the Y
chromosome, is deacetylated by HDAC3 [64]. STAT3 (signal
transducers and activators of transcription) is completely
deacetylated by HDAC3 and, to a lesser extent, by HDAC1
and HDAC2 [65]. SHP, orphan nuclear receptor, recruits
HDAC1, HDAC3, HDAC6, and SIRT1 [66, 67]. Currently,
however, the HDACs responsible for the deacetylation of
SHP are unknown. E2F1 transcription factor, which orga-
nizes early cell cycle progression, can be deacetylated by
HDAC1 via an indirect interaction mediated by Rb [68].
RelA, a class II NF-kB family member (nuclear factor kappa-
light chain enhancer of activated B cells) that acts to regulate
the immune response, can be deacetylated by HDAC3 and
SIRT1 [69, 70]. Peroxiredoxins (I and II), Hsp90, and α-
tubulin are a speciﬁc target of HDAC6 [71] .K u 7 0 ,ar e p a i r
protein, is deacetylated by SIRT1 [72]. GCM (glial cell
missing) transcription factor can be deacetylated by HDAC1,
HDAC3, HDAC4, and HDAC5 [73].
Deacetylation of non-histone proteins can alter protein
stability, localization, protein-protein interaction, DNA-
binding aﬃnity, and transcriptional activity. In addition,6 Journal of Biomedicine and Biotechnology
deacetylation of non-histone proteins promotes ubiqui-
tination and decreases the half-life of the protein [74].
Cardiac-speciﬁc transcription factors such as GATA4, NFAT,
NFκB, MEF2, SRF, Smads, Nkx2-5, YY1, Hand, Egr-1, and
C R E Ba r er e p o r t e dt ob ei n v o l v e di nh e a r td i s e a s e s .A m o n g
these, some transcription factors may be a direct target of
HDACs in the heart. For example, the MEF2D family of
transcription factors, which mediate cardiac hypertrophy,
is deacetylated by HDAC3 [75]. In addition, SIRT1, an
NAD+-dependent deacetylase, induces the acetylation of
MEF2 [51]. In contrast, although HDAC4 and HDAC5 are
known partners of MEF2, they do not function as a MEF2
deacetylase. MyoD, a skeletal muscle-speciﬁc transcription
factor, is deacetylated by HDAC1 and SIRT1 [76].
Among the six GATA transcription factors, GATA4 has
been extensively studied as a regulator of cardiac develop-
ment and diﬀerentiation as well as in hypertrophic growth in
adult heart [77–79]. Many studies have indicated that GATAs
are mainly acetylated by p300, PCAF, and CBP with HAT
activity [80]. It has been reported that GATAs can interact
withdiﬀerentHDACsalthoughlittleisknownaboutwhether
these GATAs are substrates of the HDACs. It is suggested that
GATA4maybedeacetylatedbyclassIandIIaHDACsbecause
the acetylation of GATA4 is augmented by treatment with
TSA [81].
Recent data show that the TGFβ-Smad signaling pathway
can regulate the development of cardiomyocyte hypertrophy
and cardiac ﬁbrosis. For example, Smad2 overexpression
inhibitsagonist-inducedhypertrophyinculture,andSmad4-
deﬁcient mice develop cardiac hypertrophy. Lysine residues
of Smad7, an inhibitory Smad, are deacetylated by SIRT1
(class III histone deacetylase) [82]. Smad7 overexpression
suppresses collagen type I and III whereas decreased Sma7
expression in cardiac ﬁbroblasts is found in the infarcted rat
heart [83].
The homeobox transcription factor Nkx2.5 is also impli-
cated in the hypertrophic response and in heart develop-
ment. Little is known about the direct deacetylation of
Nkx2.5 by HDACs. However, associated HDAC5 was found
in a complex with acetylated Nkx2.5 in cardiomyocytes
[84]. Thus, Nkx2.5 is expected to be a direct target of
HDACs.
YY1 is a multifunctional transcription factor that can
repress or activate the transcription of many genes. YY1
residues acetylated by p300 and PCAF are deacetylated by
HDAC1 and HDAC2 in Hela cells [85]. Recent evidence
demonstrated that YY1 interacts with HDAC5 in cardiac
myocytes and plays an anti-hypertrophic role in pathological
hypertrophy [86]. Similarly, YY1 interacts with HDAC5 in
diﬀerentiated H9c2 cells and functions as a regulator in
muscle diﬀerentiation [87]. In addition, YY1 was shown to
associate with HDAC2 and to activate the expression of BNP,
which is a marker related to cardiac myocyte hypertrophy
[88].
In addition to transcription factors, other non-histone
proteins can be regulated by deacetylation. For example, α-
tubulin, another marker of cardiac hypertrophy, is increased
in a congestive heart failure animal model. α-Tubulin was
found to be deacetylated by HDAC6 and SIRT2 [89–91].
In summary, the epigenetic modiﬁcation of diverse
proteins including heart-speciﬁc transcription factors can
play vital roles in a variety of heart diseases. The ﬁnding of
direct HDAC targets will provide us a new understanding of
pathological heart diseases and insight into promising drug
development for the treatment of cardiac hypertrophy.
7. Summary and Further Suggestions
ThefunctionalrolesoftheHDACsinheartdevelopmentand
in heart diseases including cardiac hypertrophy and heart
failure have been reviewed. Class I and IIa HDACs have been
shown to have opposing roles in the regulation of cardiac
myocyte growth and pathological heart disease. HDAC2, a
class I HDAC, induces cardiac hypertrophy in response to
early hypertrophic stimuli whereas class IIa HDACs includ-
ing HDAC4, HDAC5, and HDAC9 suppress cardiac hyper-
trophy. Several lines of evidence with HDAC inhibitors show
that class I HDACs play a more important role than class
IIa HDACs in cardiac hypertrophy. Recent work has demon-
strated that broad-spectrum HDAC inhibitors as well as
class I or II HDAC-speciﬁc inhibitors prevent cardiac hyper-
trophy, ﬁbrosis, and ischemic heart diseases. Unlike class I
and IIa HDACs, class III HDACs play an important role in
regulating oxidative stress in heart diseases with metabolic
syndromes. Future studies to develop the agonists of class III
HDACs could be a good strategy for treating and protecting
against the cardiovascular diseases associated with aging.
HDACinhibitors arebeinghighlightedascancertherapy.
SAHA, known as Vorinostat, has been approved by the Food
and Drug Administration [92], and several other HDAC
inhibitors are currently being investigated in clinical trials
[93, 94]. Thus, one can easily assume that inhibition of
HDAC may be applied for the treatment of cardiac diseases
as well as various cancers. For example, if heart-speciﬁc
HDAC inhibitors are developed and if the regulation of
HDAC activity or HDAC-interacting protein interaction
can be modulated by speciﬁc chemicals, the application of
such drugs will be of great beneﬁt. Actually, several phar-
maceutical companies are developing chemicals to regulate
HDACitselforitstarget-speciﬁcproteintotreatpathological
diseases such as in heart and muscle.
Because of their involvement in many pathological
heart diseases, further investigation of the HDACs is vital
to understand the underlying mechanism of their action,
their biological roles, and their direct substrates. The enzy-
m a t i ca c t i v i t yo fH D A C sc a nb er e g u l a t e db yp h o s p h o r y l a -
tion/dephosphorylationbyproteinkinasesandphosphatases
or by protein -protein interaction. Therefore, to improve
our understanding of the mechanism by which HDAC2
acts in cardiac hypertrophy, we will need to search for
HDAC2 kinase and other post-translational modiﬁcations
such as sumoylation, ubiquitination, S-nitrosylation, car-
bonylation (alkylation), and glycosylation. In this regard,
further studies are necessary to elucidate the mechanism
andeﬀectofnovelepigeneticregulator-mediatedcardiacdis-
eases. Further experimental evidence should be provided to
develop selective pharmacological drugs such as inhibitors ofJournal of Biomedicine and Biotechnology 7
pathology-associated HDACs or HDAC modifying enzyme
to initiate clinical trials for the treatment of cardiac diseases.
We must critically consider the non-histone targets of
HDACs.Thesetargetscontainmanyimportanttranscription
factors. Knowledge from the targets of HDAC regulation is
expectedtoimproveourcomprehensionofHDACbiological
activity and functions.
Further studies of both the downstream and the
upstream targets of HDAC2 will extend our knowledge of
the biological role of the HDACs and may suggest novel
combined therapeutic strategies for heart diseases.
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